Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.52 |
| ▸ | CTSK | P43235 | 6/20 | 0.52 |
| ▸ | CTSL | P07711 | 3/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | PTPRA | P18433 | 1/20 | 0.45 |
| ▸ | TERT | O14746 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6491657 | 0.87 | CTSS (0.47) | CTSSCTSKCTSLIDO1ACHE | |
| SCHEMBL6494201 | 0.82 | CTSS (0.54) | CTSSCTSKCTSLIDO1CTSB | |
| SCHEMBL7443477 | 0.82 | CTSL (0.72) | CTSSCTSKCTSLACHETERT | |
| SCHEMBL7439589 | 0.82 | CTSL (0.72) | CTSSCTSKCTSLACHETERT | |
| SCHEMBL10653885 | 0.81 | CTSS (0.68) | CTSSCTSKCTSLCTSBAKT1 | |
| SCHEMBL6495441 | 0.80 | TACR1 (0.51) | CTSSCTSKCTSLCTSB | |
| SCHEMBL2405030 | 0.77 | CTSS (0.74) | CTSSCTSKCTSLCTSBAKT1 | |
| SCHEMBL2442224 | 0.77 | CTSS (0.74) | CTSSCTSKCTSLCTSBAKT1 | |
| SCHEMBL2404125 | 0.77 | CTSS (0.74) | CTSSCTSKCTSLCTSBAKT1 | |
| SCHEMBL2444606 | 0.77 | CTSS (0.74) | CTSSCTSKCTSLCTSBAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256180-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | BERGMANIS ARIJA A | 2005-11-17 | — | — | US | disclosed |
| WO-2003072537-A2 | SELECTIVE PROTEIN TYROSINE PHOSPHATATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003020688-A1 | SELECTIVE PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256180-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | IRAK4, IL1B, IRAK2 | CTSS 1056/4885CTSK 300/4885CTSL 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.